Relationship between tyramine potentiation and monoamine oxidase (MAO) inhibition: comparison between moclobemide and other MAO inhibitors

@article{Zimmer1990RelationshipBT,
  title={Relationship between tyramine potentiation and monoamine oxidase (MAO) inhibition: comparison between moclobemide and other MAO inhibitors},
  author={Robert H. Zimmer},
  journal={Acta Psychiatrica Scandinavica},
  year={1990},
  volume={82}
}
  • R. Zimmer
  • Published 1990
  • Chemistry, Medicine
  • Acta Psychiatrica Scandinavica
The pharmacodynamic properties of moclobemide, a reversible inhibitor of MAO‐A (RIMA), were compared with the properties of other reversible as well as older irreversible MAO inhibitors in human subjects. All the substances supposed to have MAO‐A‐inhibitory activity, with the exception of toloxatone, were shown by the decrease in plasma DHPG or MHPG levels to cause inhibition ranging between 50% and 85%. Toloxatone and low doses of deprenyl (a MAO‐B inhibitor) caused 20% and 17% inhibition… Expand
Dopamine metabolism and neurotransmission in primate brain in relationship to monoamine oxidase A and B inhibition
TLDR
Because of their selective action on the specific forms ofMAO, which results in selective elevation of brain noradrenaline and serotonin on the one hand and dopamine and phenylethylamine on the other, it is hoped that these drugs will be able to elucidate the functional roles of MAO-A and B subtypes with regards to dopamine metabolism in the human brain. Expand
Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: focus on modulation of CNS monoamine neurotransmitter release.
TLDR
The latest advances in understanding the way in which MAO inhibitors affect the release of the monoamine neurotransmitters dopamine, noradrenaline and serotonin in the CNS are described, with an accent on the importance of these effects for the clinical actions of the drugs. Expand
Risk-Benefit Assessment of Newer Versus Older Monoamine Oxidase (MAO) Inhibitors
TLDR
Overall, RIMAs appear to represent therapeutic progress in the treatment of depression in terms of both efficacy and tolerability. Expand
Reversible Inhibitors of Monoamine Oxidase-A (RIMAs): Robust, Reversible Inhibition of Human Brain MAO-A by CX157
TLDR
CX157 is the first agent in the RIMA class with documented reversible inhibition of human brain MAO-A, supporting its classification as a R IMA, and the first RIM a with observed plasma levels that can serve as a biomarker for the degree of brain MAo-A inhibition. Expand
The new generation of monoamine oxidase inhibitors.
  • A. Cesura, A. Pletscher
  • Medicine
  • Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques
  • 1992
TLDR
In subjects with Parkinson's disease the MAO-B inhibitor L-deprenyl exerts a L-dopa-sparing effect, prolongs L- dopa action and seems to have a favorable influence regarding on-off disabilities. Expand
Clinical Pharmacology Tyramine Challenge Study to Determine the Selectivity of the Monoamine Oxidase Type B (MAO‐B) Inhibitor Rasagiline
TLDR
It is demonstrated that rasagiline selectively inhibits MAO‐B and is not associated with increased tyramine sensitivity at the indicated dose (1 mg/d), which allowed removal of dietary tyramines restriction from rasAGiline US labeling. Expand
Kinetics and metabolism of p‐tyramine during monoamine oxidase inhibition by mofegiline
The effects of monoamine oxidase B (MAO‐B) inhibition by mofegiline on the pharmacokinetics of p‐tyramine and its major metabolite, p‐hydroxyphenylacetic acid, were investigated in 24 healthy maleExpand
The Monoamine Oxidase Type B Inhibitor Rasagiline in the Treatment of Parkinson Disease: Is Tyramine a Challenge?
TLDR
It is demonstrated that rasagiline, when used at the recommended dose, is selective for MAO‐B and is not associated with heightened tyramine sensitivity, and contraindications regarding concomitant use with sympathomimetic amines are removed. Expand
The trace amine theory of spontaneous hypertension as induced by classic monoamine oxidase inhibitors
TLDR
This paper holds that TYR plays a pivotal role in causing SH, due to its strong pressor effect, and urges reconsideration, following suitable confirmation trials, of antipsychotics as these agents may reduce striatal p-TYR levels. Expand
Selectivity of MDL 72,974A for MAO-B inhibition based on substrate and metabolite concentrations in plasma.
TLDR
The increase in PEA concentrations at the higher dose may suggest that the inhibition of both forms of the enzyme is necessary to increase its plasma concentration, while plasma DOPEG concentrations do not provide a more sensitive or functional indication of MAO-B inhibition. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 14 REFERENCES
Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers.
TLDR
It is suggested that DHPG in plasma may be a useful indicator of the magnitude and duration of MAO-A inhibition in man. Expand
Tyramine potentiation during treatment with MAO inhibitors: brofaromine and moclobemide vs irreversible inhibitors.
TLDR
The results suggest that the two reversible MAO-A inhibitors Mocl and Brof may lessen the liability to TYR-related hypertensive reactions. Expand
Tyramine pressor effect in man: studies with moclobemide, a novel, reversible monoamine oxidase inhibitor.
TLDR
The potentiation by moclobemide of the pressor response to oral TYR corresponds roughly to a fourfold left shift of the TYR dose-pressor response curve and is about 10 times less marked than after tranylcypromine. Expand
Platelet MAO-B activity in humans and stumptail monkeys: in vivo effects of the reversible MAO-B inhibitor Ro 19-6327
MAO activity in platelets of six different animal species was compared with that of healthy volunteers. Only stumptail monkey (macaca arctoides) have similar high MAO-B and corresponding extremelyExpand
Clinical pharmacology of phenelzine.
TLDR
The results show that drugs such as phenelzine are effective in nonendogenous depression and phobic disorders and support a continuing role for MAO inhibitors in psychopharmacology. Expand
Platelet monoamine oxidase inhibition by deprenyl and tranylcypromine: Implications for clinical use
From the Medical College of Pennsylvania at Eastern Pennsylvania Psychiatric Institute (G.M.S., E.P.), Philadelphia, PA; the University of Southern California School of Medicine, Department ofExpand
Simultaneous liquid-chromatographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase.
TLDR
The reversed-phase liquid-chromatographic method is rapid, reliable, and simple, and it provides a more comprehensive assessment of noradrenergic nervous function than does measurement only of catecholamines. Expand
PRESSOR AMINES AND MONOAMINE-OXIDASE INHIBITORS FOR TREATMENT OF POSTURAL HYPOTENSION IN AUTONOMIC FAILURE Limitations and Hazards
The short-term effects of pressor amines were investigated in four patients with postural hypotension caused by autonomic failure. In supine patients p-tyramine alone or with a monoamine-oxidaseExpand
Tyramine infusions and selective monoamine oxidase in-COI
  • 1989
Clinical and biochemical results with toloxatone, a short-acting MAO-A inhibitor, in depressed patients
  • TIPTON KF,
  • 1984
...
1
2
...